Baseline Morbidity in 2,990 Adult African Volunteers Recruited to Characterize Laboratory Reference Intervals for Future HIV Vaccine Clinical Trials
Open Access
- 30 April 2008
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 3 (4) , e2043
- https://doi.org/10.1371/journal.pone.0002043
Abstract
An understanding of the health of potential volunteers in Africa is essential for the safe and efficient conduct of clinical trials, particularly for trials of preventive technologies such as vaccines that enroll healthy individuals. Clinical safety laboratory values used for screening, enrolment and follow-up of African clinical trial volunteers have largely been based on values derived from industrialized countries in Europe and North America. This report describes baseline morbidity during recruitment for a multi-center, African laboratory reference intervals study. Asymptomatic persons, aged 18–60 years, were invited to participate in a cross-sectional study at seven sites (Kigali, Rwanda; Masaka and Entebbe, Uganda; Kangemi, Kenyatta National Hospital and Kilifi, Kenya; and Lusaka, Zambia). Gender equivalency was by design. Individuals who were acutely ill, pregnant, menstruating, or had significant clinical findings were not enrolled. Each volunteer provided blood for hematology, immunology, and biochemistry parameters and urine for urinalysis. Enrolled volunteers were excluded if found to be positive for HIV, syphilis or Hepatitis B and C. Laboratory assays were conducted under Good Clinical Laboratory Practices (GCLP). Of the 2990 volunteers who were screened, 2387 (80%) were enrolled, and 2107 (71%) were included in the analysis (52% men, 48% women). Major reasons for screening out volunteers included abnormal findings on physical examination (228/603, 38%), significant medical history (76, 13%) and inability to complete the informed consent process (73, 13%). Once enrolled, principle reasons for exclusion from analysis included detection of Hepatitis B surface antigen (106/280, 38%) and antibodies against Hepatitis C (95, 34%). This is the first large scale, multi-site study conducted to the standards of GCLP to describe African laboratory reference intervals applicable to potential volunteers in clinical trials. Approximately one-third of all potential volunteers screened were not eligible for analysis; the majority were excluded for medical reasons.Keywords
This publication has 23 references indexed in Scilit:
- Laboratory expansion to large-scale international HIV preventive vaccine trialsCurrent Opinion in HIV and AIDS, 2007
- Micro-geographical variation in exposure to Schistosoma mansoni and malaria, and exacerbation of splenomegaly in Kenyan school-aged childrenBMC Infectious Diseases, 2004
- Immunoglobulin Levels Amongst Persons with and without Human Immunodeficiency Virus Type 1 Infection in Uganda and NorwayScandinavian Journal of Immunology, 2004
- Multiple method comparison: Statistical model using percentage similarityCytometry Part B: Clinical Cytometry, 2003
- Immunohematological Reference Ranges for Adults from the Central African RepublicClinical and Vaccine Immunology, 2003
- Causes of massive tropical splenomegaly in GhanaThe Lancet, 2002
- Ethnic and sex differences in the total and differential white cell count and platelet count.Journal of Clinical Pathology, 1996
- Serum uric acid concentrations in an urbanized South African Negro population.Annals of the Rheumatic Diseases, 1974
- NON-GENETIC NEUTROPENIA IN AFRICANSThe Lancet, 1972
- GENETIC NEUTROPENIA IN PEOPLE OF AFRICAN ORIGINThe Lancet, 1971